Tin tức & Cập nhật

Pregnant women with colorectal cancer (CRC) face a considerably increased likelihood of severe maternal morbidity, including disseminated intravascular coagulation, acute respiratory distress syndrome, and hysterectomy, among others, according to a study.

Treatment with mevrometostat (MEV), an enhancer of zeste homolog 2 inhibitor, in combination with enzalutamide (ENZ) results in better survival outcomes and response than ENZ alone among patients with metastatic castration-resistant prostate cancer (mCRPC), reports a study presented at ASCO GU 2025. The combined therapy also demonstrates a favourable safety profile.